A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge®, APC8015) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Dendreon Corporation
- 16 Feb 2019 Results of a pooled analysis of D9901, D9902A, and IMPACT trials assessing survival outcomes for African-American patients with mCRPC treated with sipuleucel-T, presented at the 2019 Genitourinary Cancers Symposium
- 18 Feb 2017 Results of survival outcomes from three phase III studies including this study presented at the 2017 Genitourinary Cancers Symposium
- 17 Sep 2013 Sipuleucel-T has been approved by the European Commission for the treatment of asymptomatic or minimally symptomatic, metastatic hormone-refractory prostate cancer. Approval was based on the results of this and 2 other trials.